Targeting Hotspot Mutations
Hotspot mutations are ideal targets for defeating cancer
Sleeping Beauty Technology
Non-viral transposition technology has favorable safety profile
Rapid, flexible & cost-effective manufacturing
hunTRTM Platform (human neoantigen T cell Receptor)
Robust discovery engine enables expansion of TCR Library
Alaunos is a clinical stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. With our robust and innovative discovery engine, we strike cancer at its core by engineering cell therapies that target Neoantigens (neoAg) arising from genomic mutations. We have developed proprietary, rapid, cost-effective solutions to deliver tumor-specific killer T cells to large cancer patient populations with unmet clinical need.
Alaunos is at the forefront of TCR therapeutics.
Learn more about Alaunos Therapeutics by filling out the form, or email us at firstname.lastname@example.org
*Each Shareholder must have their unique Control Number to cast their vote. This number can be found on your proxy mailing.